Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO

$682.65

Updated: 03/11/2026, 00:13:37

Market Cap
$252.41B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

USD
NYSE
CEO: Marc N. Casper
Employees: 125,000
https://www.thermofisher.com
Asset Summaries
Latest generated summaries for TMO

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
TMO-10-k-fy2025.html3.1 MBtext/htmlENFiled 26/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 60 KPI observations

Revenue

$44.6B

FY 2025 · Reported

Net income

$6.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$6.3B

FY 2025 · Calculated

R&D intensity

3.1%

FY 2025 · Calculated

Share repurchases

$3.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service for FY 2025. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
Consolidated
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
44,556N/A+3.9%Not disclosed by product and area
Laboratory Products and Biopharma Services
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
23,984N/A+3.6%Not disclosed by product and area
Life Sciences Solutions
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
10,374N/A+7.7%Not disclosed by product and area
Analytical Instruments
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
7,554N/A+1.2%Not disclosed by product and area
Specialty Diagnostics
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
4,676N/A+3.6%Not disclosed by product and area
Eliminations
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”
-2,033N/A+7.9%Not disclosed by product and area

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureUnited States: 49.9% of reported revenue (regional figure; not allocated by country)No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

Revenue exposure by reported geography
FY 2025 share of total net sales. Regional segments are kept as regions rather than falsely allocated to individual countries.
Other markets
+50.1%
United States
+49.9%

How the business makes money

Company overview

World leader in serving science; Mission to enable customers to make the world healthier, cleaner and safer; brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD

99%
Source evidence
“Thermo Fisher Scientific Inc. ... is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer.”

Four reportable segments

Four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services

99%
Source evidence
“We report our business in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.”

2025 acquisition of sterile fill finishing facility

2025 acquisition of a sterile fill finishing and packaging facility for U.S. manufacturing demand

85%
Source evidence
“in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity”

End markets served

Customers in pharmaceutical and biotech, academic and government, industrial and applied, healthcare and diagnostics markets

97%
Source evidence
“Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.”

Sales channels and salesforce

Direct sales force, customer-service professionals, e-commerce and third-party distributors; approximately 14,000 sales personnel

97%
Source evidence
“We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. ... approximately 14,000 sales personnel”

Specialty Diagnostics businesses

Five primary businesses: clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics and healthcare market channel

98%
Source evidence
“This segment has five primary businesses: clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics and our healthcare market channel.”

Analytical Instruments businesses

Chromatography and mass spectrometry, chemical analysis, and electron microscopy; electron microscopy serves life sciences, materials sciences, and semiconductor markets

98%
Source evidence
“This segment includes three primary businesses: chromatography and mass spectrometry, chemical analysis, and electron microscopy.”

Life Sciences Solutions businesses

Reagents, instruments and consumables for research, drug/vaccine production and diagnostics via biosciences, genetic sciences, and bioproduction businesses

98%
Source evidence
“Life Sciences Solutions includes three primary businesses: biosciences, genetic sciences, and bioproduction.”

Laboratory Products and Biopharma Services businesses

Four key businesses: laboratory products, research and safety market channel, pharma services (small- and large-molecule development/manufacturing/clinical trials), and clinical research (Phases I-IV)

98%
Source evidence
“four key businesses: laboratory products, research and safety market channel, pharma services and clinical research”

Revenues by geography 2025-2023

2025: US $22,240M, Other $22,316M, consolidated $44,556M

96%
Source evidence
“United States $22,240 $21,755 $22,013 Other 22,316 21,124 20,844 Consolidated revenues $44,556 $42,879 $42,857”

2025 segment revenues (millions USD)

2025: LSS $10,374M; AI $7,554M; SD $4,676M; LPBS $23,984M; eliminations $(2,033)M; consolidated $44,556M (2024: $9,631M/$7,463M/$4,512M/$23,157M/$(1,885)M/$42,879M)

99%
Source evidence
“Life Sciences Solutions $10,374 $9,631 Analytical Instruments 7,554 7,463 Specialty Diagnostics 4,676 4,512 Laboratory Products and Biopharma Services 23,984 23,157”

Segment revenues 2025/2024/2023

2024 external revenues: LSS $8,160M, AI $7,267M, SD $4,449M, LPBS $23,002M, consolidated $42,879M; 2023: $8,545/$7,101/$4,324/$22,888M, $42,857M

95%
Source evidence
“Revenues from external customers$8,160 $7,267 $4,449 $23,002 $42,879”

Operations and dependencies

Raw materials supply

Readily available raw materials from various sources; no single supplier material, though certain components may be sourced from a single or limited number of suppliers

95%
Source evidence
“No single supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain materials components may be sourced from a single supplier or a limited number of suppliers”

Positioning and strategy

Notable recent acquisitions

Acquired Olink Holding AB (July 10, 2024, proteomics) and Solventum's filtration and separation business (Sept 1, 2025, bioproduction filtration; expands into battery, semiconductor and medical device manufacturing)

98%
Source evidence
“On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business ... from Solventum Corporation.”

Pending acquisition of Clario Holdings

Agreement to acquire Clario for ~$8.875B cash plus $125M deferred and up to $400M contingent; expected mid-2026

98%
Source evidence
“The company has entered into an agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at the closing of the transaction”

2025 acquisition of Solventum's filtration and separation business

Acquired Solventum's filtration and separation business for $3,944M cash within Life Sciences Solutions

97%
Source evidence
“On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business”

2024 acquisition of Olink Holding AB

Acquired Olink, a Swedish proteomics provider, for $3,215M cash in July 2024

95%
Source evidence
“On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation proteomics solutions”

Risks, financing, and outlook

Total outstanding indebtedness

Approximately $39.38 billion in outstanding indebtedness as of December 31, 2025

99%
Source evidence
“we had approximately $39.38 billion in outstanding indebtedness”

Revolving credit facility

$5.00 billion unsecured multi-currency revolving credit facility

98%
Source evidence
“availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit”

Unconditional purchase obligations

Unconditional purchase obligations $1.98 billion at December 31, 2025, majority settled in 2026

95%
Source evidence
“e company's unconditional purchase obligations totaled $1.98 billion at December 31, 2025, the majority of which are expected to be settled during 2026”

2025 market and geographic revenue drivers

2025: pharma/biotech grew (offset by lower COVID-19 vaccine/therapy demand); academic/government declined on U.S. hesitancy and China macro; China sales declined while other regions grew

97%
Source evidence
“Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China.”

Material exposure graph

Pharmaceutical and biotech customers
Demand Driver

Growth in pharma and biotech demand drove 2025 revenue growth, notably bioproduction (+$548M) and pharma services (+$457M).

Relevance 92·Dependency 85·Confidence 95
Source evidence
“During 2025, revenues grew in the pharma and biotech market due to increased demand from customers”
Pharma and biotech customers
Demand Driver

Company acquired U.S. sterile fill finishing capacity to meet growing pharma/biotech demand for U.S. manufacturing.

Relevance 80·Dependency 60·Confidence 85
Source evidence
“to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity”
Academic and government customers
Demand Driver

Academic and government revenues declined in 2025 on U.S. customer hesitancy and China macro conditions — a disclosed headwind.

Relevance 70·Dependency 55·Confidence 92
Source evidence
“Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S. and macro conditions in China.”
Solventum Corporation
Supplier Dependency

Solventum was the seller of the filtration and separation business acquired for $3,944M cash.

Relevance 70·Dependency 30·Confidence 90
Source evidence
“our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics”
China
Geopolitical Exposure

China was the only disclosed geography with declining 2025 sales, attributed to macro conditions.

Relevance 65·Dependency 40·Confidence 90
Source evidence
“sales grew in North America, Europe and Asia-Pacific, but declined in China”
Tariffs
Cost Driver

Tariffs and related foreign exchange were cited as a primary driver of the Analytical Instruments segment margin decline (down 3.2 pts to 23.0%).

Relevance 60·Dependency 45·Confidence 88
Source evidence
“The decrease in segment income margin resulted primarily from the impacts of tariffs and related foreign exchange”
OECD Pillar Two
Tax Exposure

15% global minimum tax enacted or planned in numerous operating countries; company currently expects no material impact on effective tax rate.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“we currently do not expect the Pillar Two rule to have a material impact on our effective tax rate”
Regulatory approvals
Revenue Exposure

Closing of the ~$9.4B Clario acquisition is subject to regulatory approvals.

Relevance 60·Dependency 40·Confidence 85
Source evidence
“The transaction, which is expected to be completed by the middle of 2026, is subject to customary closing conditions and regulatory approvals”
US Dollar (currency translation)
Currency Exposure

Currency translation contributed 1% to 2025 revenue growth, and currency transaction gains/losses affect other income/(expense).

Relevance 55·Dependency 40·Confidence 85
Source evidence
“Impact of currency translation1 %”
Interest expense
Cost Driver

Interest expense of $1,419M vs interest income of $993M in 2025 affects pre-tax income.

Relevance 55·Dependency 35·Confidence 90
Source evidence
“Interest income993 Interest expense(1,419)”
COVID-19 vaccine and therapy related demand
Revenue Exposure

Reduced COVID-19 vaccine and therapy related demand partially offset 2025 growth; moderation also noted in Laboratory Products and Biopharma Services.

Relevance 50·Dependency 30·Confidence 85
Source evidence
“partially offset by reduced demand for COVID-19 vaccine and therapy related products and services”
Full company information
Latest profile, trading, valuation, and identifier data stored for TMO.
Share price
$682.65
Market cap
$252.41B
Exchange
NYSE
Currency
USD
CEO
Marc N. Casper
Employees
125,000
IPO date
17/03/1980
Beta
0.877
Last dividend
$0.00
Day range
$679.40 – $699.86
52-week range
$435.27 – $711.85
1-day performance
-2.06%
1-year performance
56.83%
Current drawdown (1Y)
-4.10%
CIK
0000097745
CUSIP
883556102
ISIN
US8835561023
Created
07/12/2025, 14:35:39
Last update
03/11/2026, 00:13:37

Track Thermo Fisher Scientific Inc. with an AI analyst

See which prediction-market events move TMO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to TMO from your Railway `news_articles` table.

Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript

Seeking Alpha • STOCK • 22/05/2026, 19:40:43

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

Business Wire • STOCK • 28/04/2026, 10:30:00

Thermo Fisher to Sell Microbiology Business to Astorg

WSJ • STOCK • 27/04/2026, 11:09:00

Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion

Reuters • STOCK • 27/04/2026, 10:11:17

Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities

Seeking Alpha • STOCK • 23/04/2026, 23:36:32

Thermo Fisher Scientific (NYSE: TMO) Q1 Earnings Review: Revenue Growth Amidst EPS Miss

Market Data • Market Data • 23/04/2026, 16:05:14

Thermo Fisher Scientific Inc. (TMO) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 23/04/2026, 13:31:37

Thermo Fisher (TMO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research • STOCK • 23/04/2026, 12:32:12

Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates

Zacks Investment Research • STOCK • 23/04/2026, 10:21:05

Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings

Seeking Alpha • STOCK • 20/04/2026, 13:01:45

Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research • STOCK • 16/04/2026, 13:05:56

TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?

Zacks Investment Research • STOCK • 16/04/2026, 12:20:18